Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.

摘要: Background Triple negative breast cancer (TNBC) is high-risk due to its rapid drug resistance and recurrence, metastasis, lack of targeted therapy. So far, no molecularly therapeutic agents have been clinically approved for TNBC. It imperative that we discover new targets TNBC Objectives A large volume genomics data are emerging advancing research. We may integrate different types genomic molecular Data sources used publicly available tumor tissue in the Cancer Genome Atlas database this study. Methods integratively explored profiles (gene expression, copy number, methylation, microRNA [miRNA], gene mutation) identified hyperactivated genes higher more numbers, lower methylation level, or miRNAs with expression than normal samples. ranked into levels based on all evidence performed functional analyses sets identified. More importantly, proposed potential therapy genes. Results Some such as FGFR2, MAPK13, TP53, SRC family, MUC BCL2 family suggested be treatment. Others CSF1R, EPHB3, TRIB1, LAD1 could promising By utilizing integrative analysis TNBC, hypothesized some treatment strategies currently development likely promising, poly (ADP-ribose) polymerase inhibitors, while others discouraging, angiogenesis inhibitors. Limitations The findings study need experimentally validated future. Conclusion This a systematic combined 5 characterize identify assist identifying predicting effectiveness strategy